Startseite>>Signaling Pathways>> Apoptosis>>Pitstop2

Pitstop2

Katalog-Nr.GC45549

Pitstop2 ist ein selektiver Inhibitor der Clathrin-vermittelten Endozytose (CME).

Products are for research use only. Not for human use. We do not sell to patients.

Pitstop2 Chemische Struktur

Cas No.: 1419320-73-2

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
580,00 $
Auf Lager
2mg
32,00 $
Auf Lager
5mg
49,00 $
Auf Lager
10mg
89,00 $
Auf Lager
25mg
177,00 $
Auf Lager
50mg
280,00 $
Auf Lager
100mg
456,00 $
Auf Lager
200mg
671,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 1 publications

Description Chemical Properties Product Documents Related Products

Pitstop2 is an inhibitor of the interaction between the clathrin terminal domain and amphiphysin (IC50 = 12 μM).1 It inhibits clathrin-mediated transferrin uptake in HeLa and U2OS cells (IC50s = 12-15 and 9.7 μM, respectively). Pitstop2 inhibits HIV-1 entry and infectivity in HeLa reporter cell lines. It also inhibits clathrin-independent endocytosis of CD44, CD98, and CD147 in HeLa cells.2

References
1. von Kleist, L., Stahlschmidt, W., Bulut, H., et al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell 146(3), 471-484 (2012).
2. Dutta, D., Williamson, C.D., Cole, N.B., et al. Pitstop 2 is a potent inhibitor of clathrin-independent endocytosis. PLoS One 7(9), e45799 (2012).

Bewertungen

Review for Pitstop2

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pitstop2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.